Applied Therapeutics Inc. is a biopharmaceutical company focused on developing novel therapies for the treatment of serious diseases. The company was founded in 2016 by Dr. Shoshana Shendelman, a neuroscientist and entrepreneur. Applied Therapeutics was established with the mission of addressing unmet medical needs through the discovery and development of innovative drug candidates.
The company's primary focus is on developing treatments for various conditions with an emphasis on metabolic disorders and cardiomyopathies. Applied Therapeutics' drug candidates target specific molecular pathways to address the underlying causes of these diseases, aiming to improve patient outcomes and quality of life.
An additional aspect of Applied Therapeutics' operations is its dedication to translational research and clinical development. The company's team of experts focuses on translating scientific discoveries into potential treatments, with an emphasis on addressing unmet medical needs. Applied Therapeutics has been advancing its pipeline of drug candidates through various stages of clinical trials. The company's drug development efforts encompass both small molecule compounds and biologic therapies, positioning it as a versatile player in the biopharmaceutical field.
With its commitment to developing innovative treatments for metabolic disorders and cardiomyopathies, Applied Therapeutics Inc. plays a pivotal role in the development of novel therapies that have the potential to make a positive impact on patients' lives. The company's dedication to scientific research and clinical excellence underscores its contribution to the advancement of medical treatments.